Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

organization that ThromboGenics intends to build.

Microplasmin - Diabetic Retinopathy: Phase II trial to evaluate microplasmin for the treatment of Diabetic Macular Edema (DME).

    - First unmasked data due to be presented at ASRS Conference in
      New York, 4 October, 2009

ThromboGenics is currently investigating microplasmin in the treatment of diabetic retinopathy, as it seeks to extend the range of indications for which the product could be potentially used. ThromboGenics completed the enrolment of a Phase II trial of microplasmin intravitreal injection for treatment of DME (MIVI II DME) in March 2009. The first unmasked data from this trial will be presented at the ASRS (American Society of Retina Specialists) Conference in New York on 4 October, 2009 by Professor Stalmans, KULeuven. This trial is designed as the initial step in evaluating the utility of microplasmin in patients with diabetes, a group which is more prone to eye disease such as diabetic retinopathy, due to their underlying medical condition.

Diabetic retinopathy is a major cause of visual loss and the leading cause of blindness in patients aged 20-60. Studies in this patient population have shown that there is a great variability in the type and level of adhesion seen between the vitreous and the retina.

TB-402 - Phase II trial assessing its long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery.

- Phase II trial proceeding well and ahead of schedule

TB-402 is a novel long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopedic surgery. The Phase II trial is proceeding well, with the first two cohorts (100 patients per cohort) of the study enrolled in just six months. We expect the third and final patient cohort to start recruiting shortly, after review
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
(Date:7/24/2014)... 2014 The first part of the ... First in Human Studies” will cover comprehensive clinical support ... , With increasing R&D costs and declining industry success ... maximize the knowledge collected in early Phase I/IIa study ... in late stage development. , Next, the presenters will ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... reporting of molecular diagnostic test results. It also ... necessary for the validation and reporting of high ... Molecular diagnostics is a rapidly growing area of ... disease, genetic predisposition, cancer, and companion diagnostics in ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2
... professor of materials science and engineering at Virginia ... the Friedrich Wilhelm Bessel Research Award presented by ... is for scholars, internationally renowned in their field, ... ago and who are expected to continue to ...
... Investor Uprising ( www.investoruprising.com ) has released "A Guide ... best biotech Exchange Traded Funds (ETFs) and mutual funds, ... Website. (Logo: http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a) "A ... market, identifying the leading biotech mutual funds and ETFs. ...
... 2011 Aaron Mitchell, managing principal at global management consulting ... consultants of 2011 by Consulting Magazine. Mitchell was recognized for ... over several years and during a major, recent product launch. ... the top consultants," said Mitchell, who has more than 10 ...
Cached Biology Technology:Virginia Tech's Kathy Lu receives Humboldt Foundation research award 2Investor Uprising Publishes Free Biotech Investment Report 2Investor Uprising Publishes Free Biotech Investment Report 3Managing Principal at ZS Associates Named One of Consulting Magazine's Top 25 Consultants of 2011 2
(Date:7/24/2014)... is available in German . ... Norway and they are a common sight on the roads ... cars topped the list of new vehicle registrations for the ... in Germany, where electric vehicles claim only a small portion ... roads in Germany, only a mere 8000 are electric powered. ...
(Date:7/24/2014)... a virus living inside your gut that has gone ... by researchers at San Diego State University has found ... to a newly described virus, named crAssphage, which infects ... Bacteroidetes . This phylum of bacteria is thought ... diseases. The research appears today in Nature Communications ...
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today ... the University of Massachusetts Amherst School of Public ... three-year, $700,000 Science to Achieve Results (STAR) grant ... by Native subsistence hunters in subarctic North America ... exposure and to provide culturally-relevant recommendations for mitigation. ...
Breaking Biology News(10 mins):Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3
... French . Quebec City, October 27, ... of pancreatic cells and could increase the risk of developing ... Faculty of Pharmacy. Details of this discovery were recently published ... In vitro tests conducted by Professor Frdric Picard and ...
... & Self-Service Will... -- REDWOOD SHORES, Calif., Oct. 27 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... global studies of future species shifts and losses foresees ... but offers new hope that it could be slowed ... experts Henrique Miguel Pereira and Paul Leadley, the 23-member ... DIVERSITAS, UNEP-WCMC and the secretariat of the CBD compared ...
Cached Biology News:Glucosamine causes the death of pancreatic cells 2CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 2CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 3CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 4CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 5CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 6CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 7CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 8CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 9CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 10Continuing biodiversity loss predicted but could be slowed 2Continuing biodiversity loss predicted but could be slowed 3